Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphomaSarit Assouline, Peter Martin, Solomon I. Hamburg et al.|Blood Cancer Journal|2014Cited by 48
Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory LymphomaSarit Assouline, Peter Martin, Julie Chang et al.|Blood|2012Cited by 8